Weight management can involve more than changes to eating habits and physical activity. For some people, prescription medication may be one part of a longer-term treatment plan.
GLP-1 medications have attracted considerable attention, but deciding whether treatment is appropriate requires an individual assessment. Your health history, other medications, possible side effects and ability to continue treatment all matter.
Key takeaways
- Certain GLP-1 and related medications are authorized for chronic weight management in Canada.
- Meeting an eligibility threshold does not automatically mean a medication is appropriate for you.
- Treatment involves medical follow-up alongside nutrition, physical activity and other individualized support.
- Side effects and important precautions should be discussed before starting.
- A prescription does not guarantee RAMQ or private insurance coverage.
- Weight regain can occur after treatment stops, making a longer-term plan important.
What are GLP-1 medications?
GLP-1 receptor agonists act on pathways involved in appetite and blood sugar regulation. They can help reduce hunger and food intake, and they also slow stomach emptying.
Semaglutide and liraglutide belong to this group. Tirzepatide is a related medication that acts on both GLP-1 and GIP receptors.
Different products containing the same ingredient can have different authorized uses. A product intended for diabetes treatment should not be assumed to have the same indication or instructions as a product authorized for weight management. Your physician and pharmacist can explain the specific product being considered. novonordisk.ca
Who may be eligible for weight-management medication?
For adults, the Canadian weight-management indications for semaglutide and tirzepatide include:
- A body mass index, or BMI, of 30 or higher.
- A BMI of 27 or higher, with at least one weight-related health condition.
Examples of related conditions include high blood pressure, abnormal cholesterol levels, type 2 diabetes and obstructive sleep apnea. These treatments are used alongside dietary changes and increased physical activity. novonordisk.ca
BMI is only part of the assessment. Canadian guidance emphasizes your overall health, complications, preferences and goals. Treatment should support health and quality of life, with a plan that fits your circumstances.
Meeting a BMI threshold does not guarantee a prescription. Another treatment approach may be more appropriate after reviewing the potential benefits and risks. Obesity Canada
What results can you realistically expect?
Clinical trials show that medication can support weight reduction, but study averages are not predictions for an individual patient.
In the STEP 1 trial, adults with overweight or obesity who did not have diabetes received semaglutide or a placebo alongside lifestyle support. After 68 weeks, the average reduction in body weight was 14.9% with semaglutide, compared with 2.4% with placebo.
These results came from a specific study population and treatment regimen. Some participants experienced side effects or stopped treatment. Your response may differ, and treatment decisions should consider tolerability as well as benefits. PubMed
Progress should also be discussed in terms of health, daily functioning and quality of life, rather than weight alone. Obesity Canada
What happens if you stop treatment?
Weight regain can occur after medication is stopped.
In an extension of the STEP 1 study, participants regained about two-thirds of their previous weight loss during the year after semaglutide and the structured lifestyle intervention ended. Several cardiometabolic improvements also moved back toward their starting levels.
The extension included 327 participants. It does not establish what will happen to every person, and it should not be interpreted as a result that applies equally to every medication.
Before starting treatment, discuss the longer-term plan with your physician. This includes how benefits will be assessed, what happens if side effects or costs become difficult to manage, and how care will continue if treatment ends. pubmed.ncbi.nlm.nih.gov
What side effects and risks should you discuss?
Digestive effects can include nausea, vomiting, diarrhea, constipation and abdominal discomfort. Serious risks include pancreatitis, gallbladder problems and dehydration that can affect kidney function. Low blood sugar is a particular concern when certain diabetes medications are also used.
Semaglutide and tirzepatide have important thyroid-related contraindications, including a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, known as MEN 2.
These are not complete lists. Review the patient information for the prescribed product with your clinician or pharmacist. novonordisk.ca
Seek urgent assessment for severe or persistent abdominal pain, sudden vision loss, or significant dehydration. Call 911 for a life-threatening reaction, such as severe breathing difficulty or swelling affecting the airway. pi.lilly.com
What about pregnancy, contraception or an upcoming procedure?
Tell your prescriber if you are pregnant, planning pregnancy or breastfeeding. Weight-management treatment requires a specific discussion of reproductive safety and the appropriate timing of any medication changes.
For people using oral hormonal contraception, tirzepatide’s Canadian prescribing information advises switching to a non-oral method or adding a barrier method for four weeks after starting treatment and four weeks after each dose increase. Discuss this with your prescriber. pi.lilly.com
Also tell your surgical or procedure team if you take a GLP-1 medication. Delayed stomach emptying can matter during general anaesthesia or deep sedation. The team should give you individualized instructions before the procedure. novonordisk.ca
Does RAMQ cover GLP-1 medications for weight management?
Do not assume that a prescription means a medication will be reimbursed.
RAMQ coverage depends on the specific medication, its listing and any applicable conditions. The public medication list is updated regularly, and some treatments require exceptional-medication authorization.
Coverage for a diabetes indication does not automatically establish coverage for weight management. Ask your pharmacist or prescriber to check the exact product and intended use before you commit to treatment.
You can consult RAMQ’s medication coverage information and its conditions for coverage. ramq.gouv.qc.ca
Will private insurance cover the cost?
Coverage depends on your insurance contract and the conditions attached to the medication.
Québec private prescription drug plans must provide the minimum coverage required under the public plan. Some offer broader benefits, but that does not mean every weight-management medication is included. ramq.gouv.qc.ca
Before starting, ask your insurer:
- Is this specific medication covered for weight management?
- Is prior authorization required?
- What documents must the prescriber provide?
- Are there reimbursement limits or renewal requirements?
- What portion of the cost will I pay?
Check consultation, laboratory, nutrition and medication expenses separately. Coverage for one does not establish coverage for the others.
How can you avoid fake or unauthorized products?
Obtain prescription medication from a licensed pharmacy using a valid prescription.
Health Canada warns that unauthorized or counterfeit GLP-1 products may contain incorrect amounts of medication, no active ingredient, undeclared substances or contaminants. Injectable products can also pose infection risks when manufacturing, storage or handling is unsafe.
Be cautious of sellers offering prescription medication without a prescription. A Health Canada logo or an apparent endorsement on a website is not proof that a product is authorized.
If you are unsure about a product, ask a pharmacist before using it. Health Canada’s warning about unauthorized GLP-1 products explains the risks. Canada.ca
What does weight-management care at Bina involve?
Bina Medical Clinic offers medical weight-management assessments in Brossard and by video across Québec. Care begins with at least two appointments, followed by additional visits according to your needs.
The first appointment reviews your health history, medications, previous approaches and goals. The in-clinic option includes InBody body-composition analysis and FreeStyle Libre 3 setup, with a bloodwork requisition when appropriate.
A later appointment reviews findings and suitable treatment options. Medication may be considered when clinically appropriate; an assessment does not guarantee a prescription.
You can begin with a virtual consultation when suitable. Body-composition measurements, device setup and any necessary physical examination require an in-person visit.
Appointments are billed separately. Laboratory fees and ongoing medication costs are additional. Confirm the appropriate appointment type and current fees before booking. Bina
Talk with us
To discuss medical weight management, explore Bina’s consultation options or call 514-307-0111.
The clinic can help you choose an initial appointment in Brossard or by video across Québec. Bina
Official sources and research
- Health Canada — Drug Product Database and product monographs
- Health Canada — Warning about fake or unauthorized GLP-1 products
- Obesity Canada — Pharmacotherapy guideline update
- RAMQ — Find out whether a drug is covered
- RAMQ — Information on private plans
- STEP 1 trial — Once-weekly semaglutide in adults with overweight or obesity
- STEP 1 extension — Weight regain after withdrawal of semaglutide
- Eli Lilly Canada — Tirzepatide product monograph
- Bina Medical Clinic — Weight management
This article provides general information and does not replace an individual medical assessment, diagnosis or treatment. Medication suitability, coverage and availability must be confirmed for your circumstances.
.png)
.png)
.png)
